Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
113 hedge funds and large institutions have $42.5M invested in Insys Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 22 closing their positions.
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
3% more funds holding
Funds holding: 110 → 113 (+3)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
54% less call options, than puts
Call options by funds: $253K | Put options by funds: $551K
69% less capital invested
Capital invested by funds: $136M → $42.5M (-$93M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$10.2M |
| 2 |
D.E. Shaw & Co
New York
|
+$2.18M |
| 3 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
+$1.98M |
| 4 |
Millennium Management
New York
|
+$1.78M |
| 5 |
JC
JBF Capital
Aspen,
Colorado
|
+$695K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$30.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.82M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$652K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$621K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$591K |
INSY Hedge Fund Activity: Q4 2018 in Review
113 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2018, worth a combined $42.5M — down 69% from $136M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new INSY positions and 22 closed out — a net gain of 4 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was ETF Managers Group, opening a new position worth an estimated $10.2M. The largest seller was OrbiMed, exiting entirely with an estimated $30.5M sold.
- 113 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2018, up from 110 in Q3 2018.
- Funds reported $42.5M of Insys Therapeutics, Inc. stock for Q4 2018, down 69% quarter-over-quarter.
- 26 funds opened new Insys Therapeutics, Inc. positions in Q4 2018 and 22 closed out, a net change of +4 holders.
- The largest Insys Therapeutics, Inc. buyer in Q4 2018 was ETF Managers Group, an estimated $10.2M added.
- The largest Insys Therapeutics, Inc. seller in Q4 2018 was OrbiMed, an estimated $30.5M sold.
Based on aggregated 13F filings for Q4 2018.